Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Myofibroblast-Specific TGFβ Receptor II Signaling in the Fibrotic Response to Cardiac Myosin Binding Protein C-Induced Cardiomyopathy.

Meng Q, Bhandary B, Bhuiyan MS, James J, Osinska H, Valiente-Alandi I, Shay-Winkler K, Gulick J, Molkentin JD, Blaxall BC, Robbins J.

Circ Res. 2018 Dec 7;123(12):1285-1297. doi: 10.1161/CIRCRESAHA.118.313089.

PMID:
30566042
2.

Cardiac Fibrosis in Proteotoxic Cardiac Disease is Dependent Upon Myofibroblast TGF -β Signaling.

Bhandary B, Meng Q, James J, Osinska H, Gulick J, Valiente-Alandi I, Sargent MA, Bhuiyan MS, Blaxall BC, Molkentin JD, Robbins J.

J Am Heart Assoc. 2018 Oct 16;7(20):e010013. doi: 10.1161/JAHA.118.010013.

3.

Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.

Lowey S, Bretton V, Joel PB, Trybus KM, Gulick J, Robbins J, Kalganov A, Cornachione AS, Rassier DE.

Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):11238-11243. doi: 10.1073/pnas.1802967115. Epub 2018 Oct 15.

4.

MMI-0100 Inhibits Cardiac Fibrosis in a Mouse Model Overexpressing Cardiac Myosin Binding Protein C.

Meng Q, Bhandary B, Osinska H, James J, Xu N, Shay-Winkler K, Gulick J, Willis MS, Lander C, Robbins J.

J Am Heart Assoc. 2017 Sep 4;6(9). pii: e006590. doi: 10.1161/JAHA.117.006590.

5.

An Unbiased High-Throughput Screen to Identify Novel Effectors That Impact on Cardiomyocyte Aggregate Levels.

McLendon PM, Davis G, Gulick J, Singh SR, Xu N, Salomonis N, Molkentin JD, Robbins J.

Circ Res. 2017 Sep 1;121(6):604-616. doi: 10.1161/CIRCRESAHA.117.310945. Epub 2017 Jun 27.

6.

In vivo definition of cardiac myosin-binding protein C's critical interactions with myosin.

Bhuiyan MS, McLendon P, James J, Osinska H, Gulick J, Bhandary B, Lorenz JN, Robbins J.

Pflugers Arch. 2016 Oct;468(10):1685-95. doi: 10.1007/s00424-016-1873-y. Epub 2016 Aug 27.

7.

UBC9-Mediated Sumoylation Favorably Impacts Cardiac Function in Compromised Hearts.

Gupta MK, McLendon PM, Gulick J, James J, Khalili K, Robbins J.

Circ Res. 2016 Jun 10;118(12):1894-905. doi: 10.1161/CIRCRESAHA.115.308268. Epub 2016 May 3.

8.

Phosphorylation and calcium antagonistically tune myosin-binding protein C's structure and function.

Previs MJ, Mun JY, Michalek AJ, Previs SB, Gulick J, Robbins J, Warshaw DM, Craig R.

Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3239-44. doi: 10.1073/pnas.1522236113. Epub 2016 Feb 23.

9.

Myosin-binding protein C corrects an intrinsic inhomogeneity in cardiac excitation-contraction coupling.

Previs MJ, Prosser BL, Mun JY, Previs SB, Gulick J, Lee K, Robbins J, Craig R, Lederer WJ, Warshaw DM.

Sci Adv. 2015;1(1). pii: e1400205.

10.

Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes.

Gupta MK, Gulick J, Liu R, Wang X, Molkentin JD, Robbins J.

Circ Res. 2014 Sep 26;115(8):721-9. doi: 10.1161/CIRCRESAHA.115.304760. Epub 2014 Aug 5.

11.

The protein tyrosine phosphatase Shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon.

Ehrman LA, Nardini D, Ehrman S, Rizvi TA, Gulick J, Krenz M, Dasgupta B, Robbins J, Ratner N, Nakafuku M, Waclaw RR.

J Neurosci. 2014 Mar 5;34(10):3767-78. doi: 10.1523/JNEUROSCI.3515-13.2014.

12.

Myosin-binding protein C displaces tropomyosin to activate cardiac thin filaments and governs their speed by an independent mechanism.

Mun JY, Previs MJ, Yu HY, Gulick J, Tobacman LS, Beck Previs S, Robbins J, Warshaw DM, Craig R.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2170-5. doi: 10.1073/pnas.1316001111. Epub 2014 Jan 29.

13.

Enhanced autophagy ameliorates cardiac proteinopathy.

Bhuiyan MS, Pattison JS, Osinska H, James J, Gulick J, McLendon PM, Hill JA, Sadoshima J, Robbins J.

J Clin Invest. 2013 Dec;123(12):5284-97. doi: 10.1172/JCI70877. Epub 2013 Nov 1.

14.

Functional dissection of myosin binding protein C phosphorylation.

Gupta MK, Gulick J, James J, Osinska H, Lorenz JN, Robbins J.

J Mol Cell Cardiol. 2013 Nov;64:39-50. doi: 10.1016/j.yjmcc.2013.08.006. Epub 2013 Aug 31.

15.

An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure.

Razzaque MA, Gupta M, Osinska H, Gulick J, Blaxall BC, Robbins J.

Circ Res. 2013 Aug 16;113(5):553-61. doi: 10.1161/CIRCRESAHA.113.301225. Epub 2013 Jul 12.

16.

Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes.

Xu X, Kobayashi S, Chen K, Timm D, Volden P, Huang Y, Gulick J, Yue Z, Robbins J, Epstein PN, Liang Q.

J Biol Chem. 2013 Jun 21;288(25):18077-92. doi: 10.1074/jbc.M113.474650. Epub 2013 May 8.

17.

Transgenic mouse α- and β-cardiac myosins containing the R403Q mutation show isoform-dependent transient kinetic differences.

Lowey S, Bretton V, Gulick J, Robbins J, Trybus KM.

J Biol Chem. 2013 May 24;288(21):14780-7. doi: 10.1074/jbc.M113.450668. Epub 2013 Apr 11.

18.

Phosphorylation modulates the mechanical stability of the cardiac myosin-binding protein C motif.

Michalek AJ, Howarth JW, Gulick J, Previs MJ, Robbins J, Rosevear PR, Warshaw DM.

Biophys J. 2013 Jan 22;104(2):442-52. doi: 10.1016/j.bpj.2012.12.021.

19.

Determination of the critical residues responsible for cardiac myosin binding protein C's interactions.

Bhuiyan MS, Gulick J, Osinska H, Gupta M, Robbins J.

J Mol Cell Cardiol. 2012 Dec;53(6):838-47. doi: 10.1016/j.yjmcc.2012.08.028. Epub 2012 Sep 11.

20.

Molecular mechanics of cardiac myosin-binding protein C in native thick filaments.

Previs MJ, Beck Previs S, Gulick J, Robbins J, Warshaw DM.

Science. 2012 Sep 7;337(6099):1215-8. doi: 10.1126/science.1223602. Epub 2012 Aug 23.

21.

The extent of cardiac myosin binding protein-C phosphorylation modulates actomyosin function in a graded manner.

Weith AE, Previs MJ, Hoeprich GJ, Previs SB, Gulick J, Robbins J, Warshaw DM.

J Muscle Res Cell Motil. 2012 Dec;33(6):449-59. doi: 10.1007/s10974-012-9312-y. Epub 2012 Jul 3.

22.

Circadian rhythms govern cardiac repolarization and arrhythmogenesis.

Jeyaraj D, Haldar SM, Wan X, McCauley MD, Ripperger JA, Hu K, Lu Y, Eapen BL, Sharma N, Ficker E, Cutler MJ, Gulick J, Sanbe A, Robbins J, Demolombe S, Kondratov RV, Shea SA, Albrecht U, Wehrens XH, Rosenbaum DS, Jain MK.

Nature. 2012 Feb 22;483(7387):96-9. doi: 10.1038/nature10852.

23.

Hepatitis C virus infection management in 2012.

Van Gulick JJ, Lamers MH, Drenth JP.

Panminerva Med. 2012 Mar;54(1):1-9. Review.

PMID:
22278112
24.

In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivo.

Tranter M, Liu Y, He S, Gulick J, Ren X, Robbins J, Jones WK, Reineke TM.

Mol Ther. 2012 Mar;20(3):601-8. doi: 10.1038/mt.2011.267. Epub 2011 Dec 20.

25.

Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum.

van Gulick JJ, Gevers TJ, van Keimpema L, Drenth JP.

Neth J Med. 2011 Sep;69(9):367-71. Review.

26.

Unique single molecule binding of cardiac myosin binding protein-C to actin and phosphorylation-dependent inhibition of actomyosin motility requires 17 amino acids of the motif domain.

Weith A, Sadayappan S, Gulick J, Previs MJ, Vanburen P, Robbins J, Warshaw DM.

J Mol Cell Cardiol. 2012 Jan;52(1):219-27. doi: 10.1016/j.yjmcc.2011.09.019. Epub 2011 Sep 25.

27.

Electron microscopy and 3D reconstruction of F-actin decorated with cardiac myosin-binding protein C (cMyBP-C).

Mun JY, Gulick J, Robbins J, Woodhead J, Lehman W, Craig R.

J Mol Biol. 2011 Jul 8;410(2):214-25. doi: 10.1016/j.jmb.2011.05.010. Epub 2011 May 13.

28.

A critical function for Ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function.

Sadayappan S, Gulick J, Osinska H, Barefield D, Cuello F, Avkiran M, Lasko VM, Lorenz JN, Maillet M, Martin JL, Brown JH, Bers DM, Molkentin JD, James J, Robbins J.

Circ Res. 2011 Jul 8;109(2):141-50. doi: 10.1161/CIRCRESAHA.111.242560. Epub 2011 May 19.

29.

Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.

Nakamura T, Gulick J, Pratt R, Robbins J.

Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15436-41. doi: 10.1073/pnas.0903302106. Epub 2009 Aug 24.

30.

Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.

Nakamura T, Gulick J, Colbert MC, Robbins J.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11270-5. doi: 10.1073/pnas.0902230106. Epub 2009 Jun 18.

31.

Cell-type-specific transgenesis in the mouse.

Gulick J, Robbins J.

Methods Mol Biol. 2009;561:91-104. doi: 10.1007/978-1-60327-019-9_6.

PMID:
19504066
32.

Cardiac myosin binding protein-C phosphorylation in a {beta}-myosin heavy chain background.

Sadayappan S, Gulick J, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Robbins J.

Circulation. 2009 Mar 10;119(9):1253-62. doi: 10.1161/CIRCULATIONAHA.108.798983. Epub 2009 Feb 23.

33.

Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.

Krenz M, Gulick J, Osinska HE, Colbert MC, Molkentin JD, Robbins J.

Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18930-5. doi: 10.1073/pnas.0806556105. Epub 2008 Nov 18.

34.

Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone.

Lowey S, Lesko LM, Rovner AS, Hodges AR, White SL, Low RB, Rincon M, Gulick J, Robbins J.

J Biol Chem. 2008 Jul 18;283(29):20579-89. doi: 10.1074/jbc.M800554200. Epub 2008 May 13.

35.

Regulation of transgene expression using tetracycline.

Gulick J, Robbins J.

Curr Protoc Mol Biol. 2005 Aug;Chapter 23:Unit 23.12. doi: 10.1002/0471142727.mb2312s71.

PMID:
18265363
36.

Phospholamban overexpression in transgenic rabbits.

Pattison JS, Waggoner JR, James J, Martin L, Gulick J, Osinska H, Klevitsky R, Kranias EG, Robbins J.

Transgenic Res. 2008 Apr;17(2):157-70. Epub 2007 Sep 19.

37.

Exercise reverses preamyloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy.

Maloyan A, Gulick J, Glabe CG, Kayed R, Robbins J.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5995-6000. Epub 2007 Mar 26.

38.

Imaging cellular signals in the heart in vivo: Cardiac expression of the high-signal Ca2+ indicator GCaMP2.

Tallini YN, Ohkura M, Choi BR, Ji G, Imoto K, Doran R, Lee J, Plan P, Wilson J, Xin HB, Sanbe A, Gulick J, Mathai J, Robbins J, Salama G, Nakai J, Kotlikoff MI.

Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4753-8. Epub 2006 Mar 13.

39.

Cardiac myosin-binding protein-C phosphorylation and cardiac function.

Sadayappan S, Gulick J, Osinska H, Martin LA, Hahn HS, Dorn GW 2nd, Klevitsky R, Seidman CE, Seidman JG, Robbins J.

Circ Res. 2005 Nov 25;97(11):1156-63. Epub 2005 Oct 13.

40.

Effectiveness of routine follow-up of patients treated for T1-2N0 oral squamous cell carcinomas of the floor of mouth and tongue.

Merkx MA, van Gulick JJ, Marres HA, Kaanders JH, Bruaset I, Verbeek A, de Wilde PC.

Head Neck. 2006 Jan;28(1):1-7.

PMID:
16155911
41.

Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy.

Sanbe A, Osinska H, Villa C, Gulick J, Klevitsky R, Glabe CG, Kayed R, Robbins J.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13592-7. Epub 2005 Sep 9.

42.

Forced expression of alpha-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions.

James J, Martin L, Krenz M, Quatman C, Jones F, Klevitsky R, Gulick J, Robbins J.

Circulation. 2005 May 10;111(18):2339-46. Epub 2005 May 2.

43.

Transgenic rabbit model for human troponin I-based hypertrophic cardiomyopathy.

Sanbe A, James J, Tuzcu V, Nas S, Martin L, Gulick J, Osinska H, Sakthivel S, Klevitsky R, Ginsburg KS, Bers DM, Zinman B, Lakatta EG, Robbins J.

Circulation. 2005 May 10;111(18):2330-8. Epub 2005 May 2.

44.

In vivo and in vitro analysis of cardiac troponin I phosphorylation.

Sakthivel S, Finley NL, Rosevear PR, Lorenz JN, Gulick J, Kim S, VanBuren P, Martin LA, Robbins J.

J Biol Chem. 2005 Jan 7;280(1):703-14. Epub 2004 Oct 26.

45.

Overexpression of phospholamban in slow-twitch skeletal muscle is associated with depressed contractile function and muscle remodeling.

Song Q, Young KB, Chu G, Gulick J, Gerst M, Grupp IL, Robbins J, Kranias EG.

FASEB J. 2004 Jun;18(9):974-6. Epub 2004 Apr 1.

PMID:
15059971
46.

Wegener granulomatosis: case report and brief literature review.

Shafiei K, Luther E, Archie M, Gulick J, Fowler MR.

J Am Board Fam Pract. 2003 Nov-Dec;16(6):555-9. Review. No abstract available. Erratum in: J Am Board Fam Pract. 2004 Mar-Apr;17(2):163-4.

47.

Analysis of myosin heavy chain functionality in the heart.

Krenz M, Sanbe A, Bouyer-Dalloz F, Gulick J, Klevitsky R, Hewett TE, Osinska HE, Lorenz JN, Brosseau C, Federico A, Alpert NR, Warshaw DM, Perryman MB, Helmke SM, Robbins J.

J Biol Chem. 2003 May 9;278(19):17466-74. Epub 2003 Mar 6.

48.

Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter.

Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J.

Circ Res. 2003 Apr 4;92(6):609-16. Epub 2003 Mar 6.

PMID:
12623879
49.

Benign myoepithelioma of the lung: a case report and review of the literature.

Veeramachaneni R, Gulick J, Halldorsson AO, Van TT, Zhang PL, Herrera GA.

Arch Pathol Lab Med. 2001 Nov;125(11):1494-6. Review.

PMID:
11698012
50.

Examining the in vivo role of the amino terminus of the essential myosin light chain.

Sanbe A, Gulick J, Fewell J, Robbins J.

J Biol Chem. 2001 Aug 31;276(35):32682-6. Epub 2001 Jun 29.

Supplemental Content

Loading ...
Support Center